ReviewPLoS neglected tropical diseases2019
Proposed multidimensional framework for understanding Chagas disease healthcare barriers in the United States.
Review in PLoS neglected tropical diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 60 citations in OpenAlex.
- Barriers to Chagas Disease Screening among Primary Care Providers in the United States.The American journal of tropical medicine and hygiene · 2026Article
- Catch-Up Screening to Improve Detection of Congenital Chagas Disease in a Nonendemic Setting.The American journal of tropical medicine and hygiene · 2026Article
- Towards effective coverage of Chagas disease: a community-based approach in migrant populations.International journal for equity in health · 2026Article
- Analysis of the consultations on the InfoChagas digital platform.PLoS neglected tropical diseases · 2026Article
- Estimating the health and economic burden of Chagas cardiomyopathy in the United States: a population-based analysis.Lancet regional health. Americas · 2025Article
- Changes in biodiversity drive trypanosome infections of wildlife in Panama.One health (Amsterdam, Netherlands) · 2025Article
- Chagas Disease, an Endemic Disease in the United States.Emerging infectious diseases · 2025Review
- An Evidence-Based Intervention to IncreaseOpen forum infectious diseases · 2025Article
- Diagnosing Chagas in Pregnancy and Childhood: What's Old and New.Clinics in laboratory medicine · 2025Review
- Clinician Knowledge of Chagas Disease After an Educational Intervention.JAMA network open · 2024Article
- Immunoglobulin and T cell receptor repertoire changes induced by a prototype vaccine against Chagas disease in naïve rhesus macaques.Journal of biomedical science · 2024Article
- Chagas disease in the United States: a call for increased investment and collaborative research.Lancet regional health. Americas · 2024Review
- Assessment of Community Awareness and Screening of Chagas Disease in the Latin American Community of Greater New Orleans.Tropical medicine and infectious disease · 2023Article
- Immunoglobin and T cell receptor repertoire changes induced by a prototype vaccine against Chagas disease in naïve rhesus macaques.Research square · 2023Article
- Chagas Disease Diagnostic Testing in Two Academic Hospitals in New Orleans, Louisiana: A Call to Action.Tropical medicine and infectious disease · 2023Article
- Chagas Disease and Domestic Medical Screening Guidance for Newly Arrived Individuals Under a Humanitarian-Based Immigration Status: A Call for Action.The American journal of tropical medicine and hygiene · 2022Article
- Failure to use health services by people with Chagas disease: Multilevel analysis of endemic area in Brazil.PLoS neglected tropical diseases · 2022Article
- Updated Estimates and Mapping for Prevalence of Chagas Disease among Adults, United States.Emerging infectious diseases · 2022Review
- Effect of clinician information sessions on diagnostic testing for Chagas disease.PLoS neglected tropical diseases · 2022Article
- A glimmer of hope for a neglected disease - How Chagas disease associative movement is driving progress towards disease control and elimination.Memorias do Instituto Oswaldo Cruz · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChagas disease (CD) affects over 300,000 people in the United States, but fewer than 1% have been diagnosed and less than 0.3% have received etiological treatment. This is a significant public health concern because untreated CD can produce fatal complications. What factors prevent people with CD from accessing diagnosis and treatment in a nation with one of the world's most advanced healthcare systems? METHODOLOGY/PRINCIPAL
findingsThis analysis of barriers to diagnosis and treatment of CD in the US reflects the opinions of the authors more than a comprehensive discussion of all the available evidence. To enrich our description of barriers, we have conducted an exploratory literature review and cited the experience of the main US clinic providing treatment for CD. We list 34 barriers, which we group into four overlapping dimensions: systemic, comprising gaps in the public health system; structural, originating from political and economic inequalities; clinical, including toxicity of medications and diagnostic challenges; and psychosocial, encompassing fears and stigma.
conclusionsWe propose this multidimensional framework both to explain the persistently low numbers of people with CD who are tested and treated and as a potential basis for organizing a public health response, but we encourage others to improve on our approach or develop alternative frameworks. We further argue that expanding access to diagnosis and treatment of CD in the US means asserting the rights of vulnerable populations to obtain timely, quality healthcare.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.